The Clorox Company

Technical Analysis

CLX has demonstrated impressive momentum, surging 26.8% over three months and significantly outperforming the market. The stock is trading near the midpoint of its 52-week range, suggesting it is neither overbought nor oversold. This positioning, combined with its recovery from a 37.7% drawdown, indicates room for further upside while exhibiting lower volatility than the broader market.

Fundamentals

CLX shows strong operational improvement with Q2 revenue growth of 17% and net profit margin doubling to 9.4%. The company maintains solid debt management and interest coverage, though liquidity ratios below 1.0 warrant monitoring. While return on equity is negative due to shareholder deficits, asset efficiency remains reasonable, indicating a fundamentally recovering business.

Valuation

CLX appears fairly valued on a P/E basis but potentially undervalued considering its PEG ratio of approximately 0.20, which signals strong growth prospects relative to price. However, the high EV/EBITDA ratio of 51.2 suggests the market expects significant future earnings expansion. Without direct peer comparisons, valuation leans positive based on growth expectations.

Risk Assessment

With a low beta of 0.607, CLX offers defensive characteristics but still experienced a sharp 37.7% drawdown, highlighting stock-specific risks. The absence of significant short interest and strong liquidity as a large-cap stock mitigate broader market concerns. Risks are primarily tied to execution and company-specific factors rather than market volatility.

Investment Recommendation

Considering a Buy. CLX combines strong recent momentum with improving fundamentals and attractive growth-based valuation metrics. The stock's recovery phase and defensive profile provide a balanced risk-reward opportunity, though investors should monitor liquidity and execution closely. For investors seeking stability with growth potential in consumer staples, CLX presents a compelling case.

*This analysis is for informational purposes only and does not constitute investment advice.*

RockFlow Model Forecast: Three Scenarios for 2026

Based on the comprehensive analysis, the 12-month outlook for CLX is cautiously optimistic. Key catalysts include the continuation of its impressive operational turnaround, evidenced by strong revenue growth and margin expansion, which should drive earnings and justify its growth-oriented valuation. The primary risk remains execution-related, particularly the need to sustain this recovery momentum and manage liquidity, as the company's sharp historical drawdown underscores its vulnerability to operational missteps. Given the absence of a specific analyst target, a reasonable target price range could be $140-$155, reflecting the potential for further upside as the fundamental recovery story unfolds, balanced by the stock-specific risks.

Wall Street Consensus

Most Wall Street analysts are optimistic about The Clorox Company's 12-month outlook, with consensus target around $127.16, indicating expected upside potential.

Overall, CLX has investment potential but also faces challenges. Here are key factors to weigh before investing.

CLX has demonstrated strong outperformance with substantial gains over recent periods. The stock has rebounded significantly from its cyclical lows while maintaining lower volatility characteristics relative to the broader market.

Over the past three months, CLX has surged 26.8%, significantly outperforming the market by 21.17% despite its low beta of 0.607. The 12.1% one-month gain confirms sustained upward momentum, indicating robust short-term investor confidence in the stock's trajectory.

Currently trading at $126.89, CLX sits near the midpoint of its 52-week range ($96.66-$158.91), suggesting neutral territory rather than overbought or oversold conditions. The substantial 37.7% drawdown recovery indicates the current price reflects meaningful recovery from previous weakness while leaving room for further appreciation.

Revenue & Profitability CLX demonstrated strong sequential improvement in Q2 2026, with revenue growing 17% quarter-over-quarter to $1.67 billion. Profitability metrics improved significantly, with operating income margin expanding from 8.6% to 14.4% and net profit margin doubling to 9.4%, indicating effective cost management despite persistent inflationary pressures. The gross margin expansion to 43.2% suggests improved pricing power or favorable input cost trends.

Financial Health The company maintains a manageable debt position with a 57% debt ratio and solid interest coverage of 8.6x, comfortably servicing its obligations. However, current and quick ratios below 1.0 indicate potential liquidity constraints in meeting short-term obligations, though operating cash flow generation appears adequate with a 18.6% OCF-to-sales ratio.

Operational Efficiency While return on assets remains modest at 2.8%, the negative return on equity reflects significant shareholder deficits rather than operational performance issues. Asset turnover of 0.30 suggests efficient utilization of the company's asset base, though inventory turnover of 1.56x indicates room for improvement in working capital management relative to industry peers.

Based on the PE ratios around 19.9, CLX appears to be fairly valued relative to its own earnings. The extremely high PB ratio of 438.36 reflects the company's significant intangible assets and brand value typical for consumer staples, while a PEG ratio of approximately 0.20 suggests the stock is potentially undervalued when factoring in its expected earnings growth. However, the elevated EV/EBITDA of 51.2 indicates the market is pricing in substantial future cash flows relative to current operational earnings.

A peer comparison cannot be definitively assessed as industry average data is not available. CLX's valuation metrics must therefore be evaluated in isolation, focusing on their intrinsic implications rather than relative positioning. The absence of benchmark data limits the ability to determine if CLX trades at a premium or discount to its consumer staples sector peers.

Based on its Beta of 0.607, CLX exhibits substantially lower volatility than the broader market. However, its significant one-year maximum drawdown of -37.7% highlights a considerable peak-to-trough risk, indicating the stock can still experience sharp, sustained declines despite its lower systematic risk. This disconnect suggests company-specific events have driven recent price erosion, independent of general market movements.

The lack of short interest implies minimal speculation on a price decline, which is generally a positive signal. From a liquidity perspective, as a large-cap stock, CLX is expected to have ample market depth and low transaction costs. Overall, the primary risks appear concentrated in idiosyncratic factors affecting the company's performance and valuation, rather than broader market sentiment or structural liquidity concerns.